drugset / Trial / NCT06783621

A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVÉDERM® Products, KYBELLA, CoolSculpting Elite and SkinMedica Products

NCT06783621

Phase 4 Completed 130 enrolled AbbVie
Non-randomizedParallel-groupOpen-labelTreatment

Summary

A study to evaluate overall participant satisfaction of face and neck appearance after treatment with onabotulinumtoxinA, JUVÉDERM® products, KYBELLA, CoolSculpting Elite, and select SkinMedica products in a diverse population.

Timeline

Start
2025-01-16
Primary completion
2026-03-20
Completion
2026-03-20

Drugs

EvaluationDrugModalityDoseRoute
Subject ATX-101 Peptide Other
Subject Botulinum toxin type A Protein / enzyme biologic Intramuscular

Indications

No indication recorded.